KPL: FY26 saw record revenue, margin expansion, and robust profit growth, with strong FY27 guidance

About this update from Kwality Pharmaceuticals Ltd

Record FY26 revenue and profit growth driven by margin expansion, global market gains, and operational discipline. Guidance for FY27 targets ₹650 crore revenue and ₹100 crore PAT, with strong pipeline and capacity investments supporting future growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Kwality Pharmaceuticals Ltd